<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9824bfda-37f2-4e04-951f-c666ffab28c0"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use VYEPTI safely and effectively. See full prescribing information for VYEPTI.</content>
      <br/>
      <br/>
      <content styleCode="bold">
         <content styleCode="bold">VYEPTI<sup>®</sup> (eptinezumab-jjmr) injection, for intravenous use</content>
      </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2020</content>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="79065861-6aa5-4d1f-829f-3a6471286b36"/>
   <versionNumber value="21"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="009582068" root="1.3.6.1.4.1.519.1"/>
            <name>Lundbeck Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="df79a9d9-9a8e-4afc-bcc7-7d6f7f95d92d"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250321"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67386-130" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Vyepti</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>eptinezumab-jjmr</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8202AY8I7H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPTINEZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8202AY8I7H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPTINEZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67386-130-51" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200221"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67386-130-91" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761119" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200221"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_ae57b5cf-4273-4d9a-b241-203ded34cff8">
               <id root="dff262db-94d4-416e-84de-2a9e71ada396"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (<linkHtml href="#LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">5.2</linkHtml>, <linkHtml href="#LINK_34827888-28c3-424c-a662-853b2dd713e0">5.3</linkHtml>)                     3/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0036e15c-e8f9-436a-9ec0-058399caa9da">
               <id root="b7acb4de-a378-45f5-bf41-04f12582d95f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>VYEPTI is indicated for the preventive treatment of migraine in adults.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults (<linkHtml href="#LINK_0036e15c-e8f9-436a-9ec0-058399caa9da">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_116feda9-d121-4736-a3a4-109043404f91">
               <id root="355252e9-49a1-4124-aa22-d41fa214b555"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Must dilute before use. For intravenous infusion only (<linkHtml href="#LINK_2875b08f-0769-460f-acda-7abec79982b1">2.1</linkHtml>, <linkHtml href="#LINK_e778a1a7-52da-425e-83bc-51fd7eaaa2e8">2.2</linkHtml>)</item>
                           <item>Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg (<linkHtml href="#LINK_2875b08f-0769-460f-acda-7abec79982b1">2.1</linkHtml>, <linkHtml href="#LINK_6501a631-2697-415a-9d63-6be6d8d85b42">2.3</linkHtml>)</item>
                           <item>Dilute only in 100 mL of 0.9% Sodium Chloride Injection, USP (<linkHtml href="#LINK_6501a631-2697-415a-9d63-6be6d8d85b42">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_2875b08f-0769-460f-acda-7abec79982b1">
                     <id root="1a57edc1-fcc5-4b07-9655-32cd7eb71735"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosing</title>
                     <text>
                        <paragraph>The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e778a1a7-52da-425e-83bc-51fd7eaaa2e8">
                     <id root="83b8734d-96d4-466e-86b6-991260e56e51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dilution Instructions</title>
                     <text>
                        <paragraph>VYEPTI requires dilution prior to administration. Dilute only in 100 mL 0.9% Sodium Chloride Injection, USP. The infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO). Use appropriate aseptic technique when preparing VYEPTI solution for intravenous infusion. VYEPTI single-dose vials contain no preservative; discard unused portion remaining in the vial.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dilution</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">100 mg dose:</content>
                        </paragraph>
                        <paragraph>To prepare the solution, withdraw 1 mL of VYEPTI from a single-dose vial using a sterile needle and syringe. Inject the 1 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.</paragraph>
                        <paragraph>
                           <content styleCode="italics">300 mg dose:</content>
                        </paragraph>
                        <paragraph>To prepare the solution, withdraw 1 mL of VYEPTI from each of 3 single-dose vials using a sterile needle and syringe. Inject the resulting 3 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling of Diluted Product</content>
                        </paragraph>
                        <paragraph>Gently invert the VYEPTI solution to mix completely. Do not shake. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6501a631-2697-415a-9d63-6be6d8d85b42">
                     <id root="48e30dc6-499b-42ab-ae4e-3f79b796b84d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Infusion Administration Instructions</title>
                     <text>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particulate matter or is cloudy or discolored <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_4cef0aa0-5d88-41f6-bc6e-d35697ee7b97">Dosage Forms and Strengths (3)</linkHtml>]</content>.</paragraph>
                        <paragraph>No other medications should be administered through the infusion set or mixed with VYEPTI. VYEPTI is for intravenous infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an intravenous push or bolus injection. Use an intravenous infusion set with a 0.2 micron or 0.22 micron in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4cef0aa0-5d88-41f6-bc6e-d35697ee7b97">
               <id root="19e92128-def2-400d-82a9-3423b011ef99"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution available as follows:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 100 mg/mL in a single-dose vial</item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 100 mg/mL solution in a single-dose vial (<linkHtml href="#LINK_4cef0aa0-5d88-41f6-bc6e-d35697ee7b97">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_6cddb57d-721f-45b3-9f48-5dafd1ede0a3">
               <id root="ce95120c-50bb-40a7-893d-9489353e8f5f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients (<linkHtml href="#LINK_6cddb57d-721f-45b3-9f48-5dafd1ede0a3">4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_b5804f06-38d5-4505-af85-3a312f4043c6">
               <id root="535900ac-d2fd-443c-9cf9-88121f0b6c32"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity Reactions: If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and initiate appropriate therapy (<linkHtml href="#LINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">5.1</linkHtml>) </item>
                           <item>Hypertension: New-onset or worsening of pre-existing hypertension may occur (<linkHtml href="#LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">5.2</linkHtml>)</item>
                           <item>Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur (<linkHtml href="#LINK_34827888-28c3-424c-a662-853b2dd713e0">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">
                     <id root="a8957a28-633b-4979-a1f7-c07bf50ad295"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity
Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting.<content styleCode="italics"> </content>If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_6cddb57d-721f-45b3-9f48-5dafd1ede0a3">Contraindications (4)</linkHtml> and <linkHtml href="#www.splportal.comLINK_b51bc279-4420-4c32-af4b-e2938b6266d5">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">
                     <id root="b89c1f58-b34a-4c23-b732-b2cc216cac39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Hypertension</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_34827888-28c3-424c-a662-853b2dd713e0">
                     <id root="bb68995f-15e9-426b-9749-dcf04f58a05b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Raynaud’s Phenomenon</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_722c791d-7217-45f3-a22d-cb5fe586b77e">
               <id root="305a98a8-6bfe-45af-a75e-5c50427ebedd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                     <item> Hypertension <content styleCode="italics">[see <linkHtml href="#LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Raynaud’s Phenomenon <content styleCode="italics">[see <linkHtml href="#LINK_34827888-28c3-424c-a662-853b2dd713e0">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity (<linkHtml href="#LINK_de1637b7-d724-438f-9aa6-90e3b6cdae6f">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_de1637b7-d724-438f-9aa6-90e3b6cdae6f">
                     <id root="f599b141-037f-4703-b817-781babaa354d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical
Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The safety of VYEPTI was evaluated in 2076 patients with migraine who received at least one dose of VYEPTI, representing 1615 patient-years of exposure; of these, 1524<content styleCode="bold"> </content>patients were exposed to 100 mg or 300 mg. Across all doses, 1872 patients were exposed for at least 6 months and 991 patients were exposed for 12 months. In the placebo-controlled clinical studies (Study 1 and Study 2) of 1372 patients, 579 patients received at least one dose of VYEPTI 100 mg, 574 patients received at least one dose of VYEPTI 300<content styleCode="bold"> </content>mg, and 588 patients received placebo <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1c5df93b-3ab5-4756-a345-859cac7e0327">Clinical Studies (14)</linkHtml>]</content>. Approximately 86% were female, 89% were white, and the mean age was 40.4 years at study entry.</paragraph>
                        <paragraph>The most common (incidence at least 2% and at least 2% greater than placebo) adverse reactions in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. </paragraph>
                        <paragraph>Table 1 summarizes the adverse reactions that occurred during Study 1 and Study 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1.       Adverse Reactions Occurring with an Incidence of at Least 2% for VYEPTI and at Least 2% Greater than Placebo in Studies 1 and 2</content>
                        </paragraph>
                        <table width="712.03px" cellspacing="0" cellpadding="0" border="1">
                           <col width="25.18%"/>
                           <col width="25.04%"/>
                           <col width="24.44%"/>
                           <col width="25.34%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode=" Botrule Toprule Lrule Rrule">Adverse Reactions</th>
                                 <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI 100 mg N=579%</th>
                                 <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI 300 mg N=574%</th>
                                 <th align="center" styleCode=" Botrule Toprule Lrule Rrule">Placebo N=588%</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypersensitivity reactions*</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Hypersensitivity reactions includes multiple related adverse event terms, such as hypersensitivity, pruritus, and flushing/hot flush that occurred on the day of dosing.</paragraph>
                        <paragraph>In Study 1 and Study 2, 1.9% of patients treated with VYEPTI discontinued treatment because of adverse reactions <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_02673df2-ac5e-47b7-8a0c-c2eeefe84093">
                     <id root="caa75704-7387-4ac3-b95d-fa14ca3de99d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Immunogenicity</title>
                     <text>
                        <paragraph>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and speciﬁcity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be inﬂuenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to eptinezumab-jjmr in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</paragraph>
                        <paragraph>In patients receiving VYEPTI 100 mg or 300 mg every 3 months, the incidence of anti-eptinezumab-jjmr antibody development in Study 1 (up to 56 weeks) was 20.6% (92/447), and 41.3% (38/92) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. In Study 2 (up to 32 weeks), the incidence of anti-eptinezumab-jjmr antibody development was 18.3% (129/706), and 34.9% (45/129) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. In an open-label study with 84 weeks of treatment, 18% (23/128) of patients developed anti-eptinezumab-jjmr antibodies, and 39% (9/23) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. </paragraph>
                        <paragraph>Although the results from both studies showed no clear evidence of an impact from development of anti-eptinezumab-jjmr antibodies, including neutralizing antibodies, on the safety and efficacy profiles of VYEPTI, the available data are too limited to make definitive conclusions.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e0481435-7112-40d6-b06d-a90d7defccec">
                     <id root="58b9bde2-7ed7-49bd-8916-b01b76536a7c"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.3 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of VYEPTI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders: </content>Anaphylaxis <content styleCode="italics">[see <linkHtml href="#LINK_6cddb57d-721f-45b3-9f48-5dafd1ede0a3">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions: </content>Fatigue</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders: </content>Hypertension<content styleCode="italics"> [see <linkHtml href="#LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">Warnings and Precautions (5.2)</linkHtml>]</content>, Raynaud’s phenomenon <content styleCode="italics"> </content>
                           <content styleCode="italics">[see <linkHtml href="#LINK_34827888-28c3-424c-a662-853b2dd713e0">Warnings and Precautions (5.3)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9ed900aa-ceb6-4d8b-9521-e4768d5b3bd1">
               <id root="473f5112-a885-4bce-a535-dca651ce071b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_4f6e903e-f794-4e51-9a62-4284d4021f6d">
                     <id root="961f7868-64ff-4dfe-82e7-fb703167fb7c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VYEPTI during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-855-810-8549 or by contacting the company at www.vyeptipregnancyregistry.lundbeck.com.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate data on developmental risks associated with the use of VYEPTI in pregnant women.</paragraph>
                        <paragraph>No adverse developmental effects were observed following administration of eptinezumab-jjmr to pregnant animals at doses greater than those used clinically <content styleCode="italics">[see Data]</content>. </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>When eptinezumab-jjmr (0, 75, or 150 mg/kg) was administered weekly to female rats and rabbits by intravenous injection throughout organogenesis, no adverse effects on embryofetal development were observed. The higher dose tested (150 mg/kg) is 30 times the maximum recommended human dose (MRHD) of 300 mg, on a body weight basis (mg/kg).</paragraph>
                        <paragraph> When eptinezumab-jjmr (0, 75, or 150 mg/kg) was administered weekly to female rats throughout pregnancy and lactation, no adverse effects on pre- and postnatal development were observed. The higher dose tested (150 mg/kg) is 30 times the MRHD, on a mg/kg basis.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2360b3b5-9219-41d6-a57f-2c590af9e09b">
                     <id root="4701514d-c76d-4ba7-a2b7-28d267a90880"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_66286a2b-7759-409c-a93f-5bf87889ca2b">
                     <id root="23b54b27-2a8e-48c4-9ea0-2f2d050941f8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_29fa6c16-d326-4ed3-b235-76734cc0c38b">
                     <id root="f6530878-fcad-4013-a2ea-f3a00685e01b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7ed0975d-d0c2-465e-aeef-d5e55e935595">
               <id root="ce774d7a-ae3c-46a2-a584-276c602823cd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Eptinezumab-jjmr has an approximate molecular weight of 143 kD. Eptinezumab-jjmr is produced in <content styleCode="italics">Pichia pastoris</content> yeast cells by recombinant DNA technology. </paragraph>
                  <paragraph>VYEPTI (eptinezumab-jjmr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to brownish-yellow solution, for intravenous infusion. VYEPTI is supplied as a 100 mg/mL single-dose vial. Each mL contains 100 mg eptinezumab-jjmr formulated in L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="LINK_f9e99848-b994-4855-b3b7-ce8d079c89ad">
               <id root="515f420d-b703-42ca-9e33-01c3bf4c1068"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_43099f32-907a-44cc-b9ba-a0fd8a4527da">
                     <id root="103ab0fd-c0ab-4b43-8c7c-f2730c17ba2a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_33d4ee1b-097a-442f-ab52-57de89f70c5f">
                     <id root="d32323e8-6f08-4ee2-a235-370ac4043935"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The relationship between the pharmacodynamic activity and the mechanism(s) by which eptinezumab-jjmr exerts its clinical effects is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_30557d7d-ec97-48aa-acdf-23306d21a3f1">
                     <id root="d31719ff-7a1a-470b-b57a-0a428133b8ca"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Eptinezumab-jjmr exhibits linear pharmacokinetics and exposure increases proportionally with doses from 100 mg to 300 mg after intravenous administration. Steady-state plasma concentration is attained after the first dose with a once every 3-month dosing schedule.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The central volume of distribution (Vc) for eptinezumab-jjmr is approximately 3.7 liters.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism &amp; Elimination</content>
                        </paragraph>
                        <paragraph>Eptinezumab-jjmr is expected to be degraded by proteolytic enzymes into small peptides and amino acids. </paragraph>
                        <paragraph>The apparent clearance of eptinezumab-jjmr was 0.006 L/h, and the terminal elimination half-life was approximately 27 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>A population pharmacokinetic analysis assessing the effects of age, race, sex, and body weight did not suggest any clinically significant impact of these covariates on eptinezumab exposures. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal or Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>No dedicated studies were conducted to assess the effects of renal or hepatic impairment on the pharmacokinetics of eptinezumab-jjmr. However, hepatic or renal impairment is not expected to affect the pharmacokinetics of eptinezumab-jjmr. A population pharmacokinetic analysis of integrated data from eptinezumab-jjmr clinical studies did not reveal clinically significant impact on pharmacokinetics of patients with hepatic or renal impairment. </paragraph>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">P450 Enzymes</content>
                        </paragraph>
                        <paragraph>Eptinezumab-jjmr is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Sumatriptan</content>
                        </paragraph>
                        <paragraph>The co-administration of a single dose of 300 mg eptinezumab-jjmr administered as an intravenous infusion (over a period of 1 hour ± 15 min) with a single dose of 6 mg sumatriptan administered subcutaneously did not significantly influence the pharmacokinetics of eptinezumab-jjmr or sumatriptan.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_541d879c-e314-40d8-9d25-9f58414d142e">
               <id root="bf553675-3e65-4c52-a4b2-80371e2331ae"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_2bfa92bb-b10d-44dc-b76e-eabb2cff30bd">
                     <id root="ee444805-2650-4678-ba35-e8594b0894da"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>The carcinogenic potential of eptinezumab-jjmr has not been assessed. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Genetic toxicology studies of eptinezumab-jjmr have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>When eptinezumab-jjmr (0, 75, or 150 mg/kg) was administered weekly by intravenous injection to male and female rats prior to and during mating and continuing in females to gestation day 3-4, no adverse effects on fertility were observed. The higher dose tested (150 mg/kg) is 30 times the maximum recommended human dose of 300 mg, on a body weight basis (mg/kg). </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1c5df93b-3ab5-4756-a345-859cac7e0327">
               <id root="d2b59481-d3ed-4dcc-8482-1aae67f46386"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of VYEPTI was evaluated as a preventive treatment of episodic and chronic migraine in two randomized, multicenter, placebo-controlled studies, both with 6-month double-blind periods: one study in patients with episodic migraine (Study 1) and one study in patients with chronic migraine (Study 2). VYEPTI was administered by intravenous infusion every 3 months in both studies; however, the primary endpoint was measured at 12 weeks. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Study 1: Episodic Migraine</content>
                  </paragraph>
                  <paragraph>Study 1 (NCT02559895) included adults with a history of episodic migraine (4 to 14 headache days per month, of which at least 4 were migraine days). A total of 665 patients were randomized to receive placebo (N=222), 100 mg VYEPTI (N=221), or 300 mg VYEPTI (N=222) every 3 months for 12 months. Patients were allowed to use concurrent acute migraine or headache medications, including migraine-specific medications (i.e., triptans, ergotamine derivatives), during the trial.</paragraph>
                  <paragraph>The study excluded patients with a history of cardiovascular disease (hypertension, ischemic heart disease), neurological disease, or cerebrovascular disease. </paragraph>
                  <paragraph>The primary efficacy endpoint was the change from baseline in mean monthly migraine days over Months 1-3. Secondary endpoints included the percentages of patients with 50% or greater, and 75% or greater reductions from baseline in monthly migraine days over Months 1-3. </paragraph>
                  <paragraph>Patients had a median age of 39 years (range: 18 to 71 years), 84% were female, and 84% were white. The mean migraine frequency at baseline was approximately 8.6 migraine days per month and was similar across treatment groups. </paragraph>
                  <paragraph>VYEPTI treatment demonstrated statistically significant improvements compared to placebo for the primary efficacy endpoint, as shown in Table 2; secondary endpoints are also summarized in Table 2.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2.       Efficacy Endpoint Results in Study 1</content>
                  </paragraph>
                  <table width="712.22px" cellspacing="0" cellpadding="0">
                     <col width="25.18%"/>
                     <col width="25.04%"/>
                     <col width="24.44%"/>
                     <col width="25.34%"/>
                     <thead>
                        <tr>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI 100 mg N=221</th>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI 300 mg N=222</th>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">Placebo N=222</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Monthly Migraine Days (MMD) – Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Change from baseline</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> -3.9</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-4.3 </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-3.2 </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> -0.7</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> -1.1</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="italics">p</content>-value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0.018</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> &lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold"> ≥50% MMD responders – Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> % Responders</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 49.8%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 56.3%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 37.4%</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12.4%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 18.9%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="italics">
                                 <content styleCode="italics">p</content>-</content>value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.009*<br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001<br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold"> ≥75% MMD responders – Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> % Responders</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22.2%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 29.7%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 16.2%</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 6.0%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13.5%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="italics">p</content>-value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NS**</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> &lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>              * Nominal statistical significance</paragraph>
                  <paragraph>              ** NS = Not statistically significant</paragraph>
                  <paragraph>Figure 1 shows the mean change from baseline in average monthly migraine days in Study 1. Patients treated with VYEPTI at both doses had greater mean decreases from baseline in mean monthly migraine days over Months 1-3 compared to placebo-treated patients. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1.       Change from Baseline in Monthly Migraine Days in Study 1</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Figure 2 shows the distribution of change from baseline in mean monthly migraine days through Month 3 by treatment group in 2-day increments.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2.       Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1 to 3 by Treatment Group in Study 1</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>Figure 3 demonstrates that greater percentages of placebo-treated patients had migraines on most days during the first 7 days of treatment compared to VYEPTI-treated patients in Study 1.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 3.       Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 1</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>
                     <content styleCode="underline">Study 2: Chronic Migraine</content>
                  </paragraph>
                  <paragraph>Study 2 (NCT02974153) included adults with a history of chronic migraine (15 to 26 headache days per month, of which at least 8 were migraine days). A total of 1072 patients were randomized and received placebo (N=366), 100 mg VYEPTI (N=356), or 300 mg VYEPTI (N=350) every 3 months for 6 months. Patients were allowed to use and to continue an established stable regimen of acute migraine or headache preventive medication (except onabotulinumtoxinA). Patients with a dual diagnosis of chronic migraine and medication overuse headache attributable to acute medication overuse (triptans, ergotamine, or combination analgesics greater than 10 days per month) were included in the study population. Patients using opioids or butalbital-containing products greater than 4 days per month were not allowed. </paragraph>
                  <paragraph>The study excluded patients with a history of cardiovascular disease (hypertension, ischemic heart disease), neurological disease, or cerebrovascular disease.</paragraph>
                  <paragraph>The primary efficacy endpoint was the change from baseline in mean monthly migraine days over Months 1-3. Secondary endpoints included the percentages of patients with 50% or greater and 75% or greater reductions from baseline in monthly migraine days over Months 1-3.</paragraph>
                  <paragraph>Patients had a median age of 41 years (range: 18 to 65 years), 88% were female, and 91% were white. Forty-one percent of patients were taking concomitant preventive medication for migraine. The mean migraine frequency at baseline was approximately 16.1 migraine days per month and was similar across treatment groups. </paragraph>
                  <paragraph>VYEPTI treatment demonstrated statistically significant improvements compared to placebo for the primary efficacy endpoint, as shown in Table 3; secondary endpoints are also summarized in Table 3.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 3.       Efficacy Endpoint Results in Study 2</content>
                  </paragraph>
                  <table width="712.22px" cellspacing="0" cellpadding="0">
                     <col width="25.18%"/>
                     <col width="25.04%"/>
                     <col width="24.44%"/>
                     <col width="25.34%"/>
                     <thead>
                        <tr>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI100 mg N=356</th>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">VYEPTI300 mg N=350</th>
                           <th align="center" styleCode=" Botrule Toprule Lrule Rrule">Placebo N=366</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Monthly Migraine Days (MMD) – Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Change from baseline</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-7.7</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-8.2</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-5.6</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-2.0</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">-2.6</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="italics">p-</content>value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">≥50% MMD responders –Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">% Responders</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">57.6%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">61.4%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">39.3%</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">18.2%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">22.1%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="italics">
                                 <content styleCode="italics">p</content>-</content>value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001<br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001<br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">≥75% MMD responders –Months 1-3</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">% Responders</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">26.7%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">33.1%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15.0%</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Difference from placebo</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11.7%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">18.1%</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="italics">p</content>-value</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt;0.001</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Figure 4 shows the mean change from baseline in average monthly migraine days for Study 2. Patients treated with VYEPTI at both doses had greater mean decreases from baseline in mean monthly migraine days over Month 1-3 compared to placebo-treated patients.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 4.       Change from Baseline in Monthly Migraine Days in Study 2</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph>Figure 5 shows the distribution of change from baseline in mean monthly migraine days through Month 3 by treatment group in 3-day increments.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 5.       Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1-3 by Treatment Group in Study 2</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph>Figure 6 demonstrates that greater percentages of placebo-treated patients had migraines on individual days during the first 7 days of treatment compared to VYEPTI-treated patients in Study 2.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 6.       Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 2</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 1. Change from Baseline in Monthly Migraine Days in Study 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure 2. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1 to 3 by Treatment Group in Study 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure 3. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure 4. Change from Baseline in Monthly Migraine Days in Study 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure 5. Distribution of Change from Baseline in Mean Monthly Migraine Days over Months 1-3 by Treatment Group in Study 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure 6. Percentage of Patients with a Migraine from Day -1 (Day Prior to Infusion) to Day 7 in Study 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9cfeda77-7bc6-476f-ae11-41990e346334">
               <id root="c6a64132-d393-4586-a87c-2b7d3ef94a12"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text/>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="LINK_2eed80e0-6249-4f26-88c0-d26f966627b4">
                     <id root="ba5ce2e2-fc7b-486d-823b-3b51ceb46f9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>VYEPTI (eptinezumab-jjmr) injection is a clear to slightly opalescent, colorless to brownish-yellow solution supplied as:</paragraph>
                        <paragraph>          Carton containing one 100 mg/mL single-dose vial - NDC 67386-130-51.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c9d43308-f33c-44a9-ba5e-a2ba9ad21805">
                     <id root="21252b7b-664e-4d66-b259-d2b9e55f43d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.</paragraph>
                        <paragraph>The vial stopper is not made with natural rubber latex.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b51bc279-4420-4c32-af4b-e2938b6266d5">
               <id root="7c3b5d38-e852-4964-9ee1-971bec08d5b9"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="italics"> </content>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur with VYEPTI. Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_a24fdf92-fd8b-45ec-ac05-eef4cad1c9ca">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypertension </content>
                  </paragraph>
                  <paragraph>Inform patients that hypertension can develop or pre-existing hypertension can worsen with VYEPTI, and that they should contact their healthcare provider if they experience elevation in their blood pressure <content styleCode="italics">[see <linkHtml href="#LINK_0a4132b6-fa5e-43ec-8a0e-e4f681e6fa1c">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Raynaud’s Phenomenon </content>
                  </paragraph>
                  <paragraph>Inform patients that Raynaud’s phenomenon can develop or worsen with VYEPTI. Advise patients to discontinue VYEPTI treatment and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon <content styleCode="italics">[see <linkHtml href="#LINK_34827888-28c3-424c-a662-853b2dd713e0">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Exposure Registry</content>
                  </paragraph>
                  <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VYEPTI during pregnancy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_4f6e903e-f794-4e51-9a62-4284d4021f6d">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Inform patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_2360b3b5-9219-41d6-a57f-2c590af9e09b">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Lundbeck Seattle BioPharmaceuticals, Inc. </paragraph>
                  <paragraph>11804 North Creek Parkway South</paragraph>
                  <paragraph>Bothell, WA 98011 USA</paragraph>
                  <paragraph> U.S. License No. 2097</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
                  <paragraph>Vyepti is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>Lundbeck Logo 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bcf7df28-712e-41c3-a625-dde95541ecd5">
               <id root="98b27653-5f44-428c-b2af-4b4b9c854d7c"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT PACKAGE INSERT</title>
               <text>
                  <table width="95%" cellspacing="0" cellpadding="0">
                     <col width="534.95pt"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>VYEPTI<sup>®</sup>(vye ep' tee)</paragraph>
                              <paragraph>(eptinezumab-jjmr)</paragraph>
                              <paragraph>injection, for intravenous use</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is VYEPTI?</content>
                              </paragraph>
                              <paragraph>VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.</paragraph>
                              <paragraph>It is not known if VYEPTI is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Do not receive VYEPTI</content> if you are allergic to eptinezumab-jjmr or any of the ingredients in VYEPTI. See the end of this Patient Information leaflet for a complete list of ingredients in VYEPTI.                                                      </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before you receive VYEPTI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have high blood pressure.</item>
                                 <item>have circulation problems in your fingers and toes.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if VYEPTI will harm your unborn baby.
                <list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="underline">Pregnancy Registry</content>: There is a pregnancy registry for women who take VYEPTI. The purpose of this registry is to collect information about the health of you and your baby. You may enroll yourself by calling 1-855-810-8549 or by visiting <linkHtml href="http://www.vyeptipregnancyregistry.lundbeck.com/">www.vyeptipregnancyregistry.lundbeck.com</linkHtml>. Or you may talk to your healthcare provider about how you can take part in this registry.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if VYEPTI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using VYEPTI.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How will I receive VYEPTI?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>VYEPTI will be given by a healthcare provider in a healthcare setting. </item>
                                 <item>VYEPTI is given by intravenous (IV) infusion in your vein.</item>
                                 <item>VYEPTI will be given over 30 minutes every 3 months. </item>
                              </list>
                              <paragraph>If you have questions about your infusion schedule, ask your healthcare provider.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of VYEPTI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">VYEPTI may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Allergic reactions. </content>Allergic reactions can happen after receiving VYEPTI. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms of an allergic reaction:
                <paragraph>o rash</paragraph>
                                    <paragraph>o swelling of your face, lips, tongue or throat </paragraph>
                                    <paragraph>o trouble breathing</paragraph>
                                    <paragraph>o hives</paragraph>
                                    <paragraph>o redness in your face</paragraph>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="bold">High blood pressure. </content>
                                    </content>High blood pressure or worsening of high blood pressure can happen after receiving VYEPTI. Contact your healthcare provider if you have an increase in blood pressure.  </item>
                                 <item>
                                    <content styleCode="bold">Raynaud’s phenomenon.</content> A type of circulation problem can worsen or happen after receiving VYEPTI. Raynaud’s phenomenon can lead to your fingers or toes feeling numb, cool, or painful, or changing color from pale, to blue, to red. Contact your healthcare provider if these symptoms occur.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of VYEPTI include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>stuffy nose and scratchy throat</item>
                                 <item>allergic reactions</item>
                              </list>
                              <paragraph>These are not all of the possible side effects of VYEPTI. </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of VYEPTI.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information about VYEPTI that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in VYEPTI?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient</content>: eptinezumab-jjmr</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients</content>: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sorbitol, and Water for Injection.</paragraph>
                              <paragraph>The vial stopper is not made with natural rubber latex.</paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Manufactured by: Lundbeck Seattle BioPharmaceuticals, Inc., 11804 North Creek Parkway South, Bothell, WA 98011</content>
                              </paragraph>
                              <paragraph>US License Number: 2097</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Lrule Rrule"> <renderMultiMedia referencedObject="MM8"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Lrule Rrule">Vyepti is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc.
            <paragraph>For more information, call 1-833-4-VYEPTI (833-489-3784) or go to www.Vyepti.com</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                                                                    Revised: 3/2025</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>Lundbeck</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cae19ddf-f04c-4eb8-b025-a36eef655660">
               <id root="dd959a13-7e17-42ac-a601-d816c0905d53"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 67386-130-51</paragraph>
                  <paragraph>VYEPTITM (vye ep' tee)</paragraph>
                  <paragraph>(eptinezumab-jjmr)</paragraph>
                  <paragraph>injection, for intravenous use</paragraph>
                  <paragraph>100 mg/mL<renderMultiMedia referencedObject="MM9"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>NDC 67386-130-51 VYEPTITM (vye ep' tee) (eptinezumab-jjmr) injection, for intravenous use 100 mg/mL injection, for intravenous use 100 mg/mL</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_04ed4226-7ecd-41e0-845d-9ff016c18970">
               <id root="6cd10aca-e7eb-43d7-bfc4-18b307584a82"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 67386-130-91<br/>
                     <br/>
VYEPTITM (vye ep' tee)<br/>
                     <br/>
(eptinezumab-jjmr)<br/>
                     <br/>
injection, for intravenous use<br/>
                     <br/>
100 mg/mL<br/>
                     <br/>
Professional Sample<renderMultiMedia referencedObject="MM10"/>
                  </paragraph>
                  <paragraph>Professional Sample</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>NDC 67386-130-91 VYEPTITM (vye ep' tee) (eptinezumab-jjmr) njection, for intravenous use 100 mg/mL Professional Sample</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyepti-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>